Literature DB >> 7999346

Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease.

M A Raskind1, E R Peskind.   

Abstract

Abnormalities of neurochemical systems in Alzheimer disease, which are potentially relevant to the pathophysiology of such noncognitive problems as agitation and depression, have been demonstrated. However, the role of these abnormalities in the etiology of noncognitive problem behaviors remains poorly understood. Such abnormalities in brain noradrenergic and serotonergic systems are of particular interest because of their apparent involvement in normal regulation of mood, arousal, and aggressive behavior. The nature of the noradrenergic abnormalities in Alzheimer disease is particularly complex, with evidence suggesting both structural damage and compensatory increased norepinephrine release from remaining noradrenergic neurons. Currently available drugs that alter brain noradrenergic or serotonergic activity should be evaluated for efficacy in the management of noncognitive behavioral disorders complicating Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999346

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  15 in total

Review 1.  Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.

Authors:  D I Kaufer
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  The biological basis of behavioral symptoms in dementia.

Authors:  L Garand; K C Buckwalter; G R Hall
Journal:  Issues Ment Health Nurs       Date:  2000 Jan-Feb       Impact factor: 1.835

Review 3.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 4.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

5.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 6.  Towards defining restlessness in individuals with dementia.

Authors:  Natalie G Regier; Laura N Gitlin
Journal:  Aging Ment Health       Date:  2016-01-08       Impact factor: 3.658

Review 7.  Non-Pharmacological Approaches to Reducing Negative Behavioral Symptoms: A Scoping Review.

Authors:  Carin Wong; Natalie E Leland
Journal:  OTJR (Thorofare N J)       Date:  2016-01

Review 8.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.

Authors:  David Weinshenker
Journal:  Trends Neurosci       Date:  2018-02-20       Impact factor: 13.837

9.  Dementia-related restlessness: relationship to characteristics of persons with dementia and family caregivers.

Authors:  Natalie G Regier; Laura N Gitlin
Journal:  Int J Geriatr Psychiatry       Date:  2017-03-23       Impact factor: 3.485

10.  β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade.

Authors:  Fang Zhang; Mary Gannon; Yunjia Chen; Shun Yan; Sixue Zhang; Wendy Feng; Jiahui Tao; Bingdong Sha; Zhenghui Liu; Takashi Saito; Takaomi Saido; C Dirk Keene; Kai Jiao; Erik D Roberson; Huaxi Xu; Qin Wang
Journal:  Sci Transl Med       Date:  2020-01-15       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.